治疗耐药性类风湿性关节炎的病理生理学和分层
Saeko Yamada1, Yasuo Nagafuchi1,2, Keishi Fujio1
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Immunological medicine
|July 18, 2023
概括
了解耐治疗性类风湿性关节炎 (RA) 是关键. 本综述探讨了免疫机制,确定了两个RA亚组,基于免疫反应的不同预后,为精准医学铺平了道路.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 遗传学 遗传学 是一个
背景情况:
- 风湿性关节炎 (RA) 的早期诊断和治疗具有挑战性,特别是在治疗耐药性疾病的患者中.
- 耐火性RA背后的免疫机制尚不清楚.
- 在RA中治疗耐药性的遗传预测是复杂的.
研究的目的:
- 审查和总结现有关于抗治疗性RA的免疫机制的研究.
- 提出一种新的假设,以基于免疫病理学的基础,将RA患者分为不同的亚组.
- 探索潜在的生物标志物来预测RA的治疗反应和预后.
主要方法:
- 关于治疗耐药性RA免疫机制的先前研究结果的全面审查.
- 分析B细胞,T细胞,其他免疫细胞和纤维细胞在RA病理生理学和治疗反应中的作用.
- 免疫学分析以将RA患者分成具有独特免疫学特征的子组.
主要成果:
- 患有或没有抗周期性氨酸自身抗体的患者代表了不同的亚组,预后和治疗反应不同.
- 免疫细胞和纤维细胞起着重要的病理生理作用,并影响RA的治疗结果.
- 一个新的假设提出了两个RA子组:一个具有良好的预后 (增加干扰素信号) 和另一个具有更糟糕的预后 (增强的获得免疫反应).
结论:
- 独特的免疫病理是RA亚组的特征,影响预后和治疗反应.
- 增加的干扰素信号与一个RA亚组的良好预后有关.
- 增强的获得性免疫反应,增加的树突细胞前体和多样化的自身反应性抗体可能标志着预后较差的RA亚组,指导未来的精准医学方法.
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
01:23Rheumatic Heart Disease I: Introduction
17
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
17
01:24T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
38
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
01:20Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465